RAPID-PsA: improvements in productivity in the workplace and within the home at week 24 (RS population, LOCF)
| Placebo | CZP 200 mg Q2W | CZP 400 mg Q4W | CZP 200 mg – Placebo Mean diff (95% CI) (p value) | CZP 400 mg – Placebo Mean diff (95% CI) (p value) | |
|---|---|---|---|---|---|
| Mean | |||||
| Productivity at the workplace over previous month (employed patients only) | n=76 | n=84 | n=84 | ||
| Work days missed due to arthritis | 1.6 | 0.2 | 0.6 | −1.4 (−3.4 to −0.6) (<0.001) | −1.0 (−2.8 to −0.1) (0.060) |
| Days with work productivity reduced by ≥50% due to arthritis* | 3.5 | 1.3 | 2.1 | −2.2 (−4.1 to −0.7) (0.003) | −1.4 (−3.4 to 0.6) (0.176) |
| Rate of arthritis interference with work productivity† | 3.2 | 1.7 | 1.9 | −1.4 (−2.3 to −0.7) (<0.001) | −1.2 (−2.1 to −0.4) (0.004) |
| Productivity at home and daily activities over previous month | n=136 | n=138 | n=135 | ||
| Days with no household work due to arthritis | 4.7 | 2.5 | 2.4 | −2.3 (−4.0 to −0.7) (0.007) | −2.2 (−3.9 to −0.6) (0.010) |
| Days with household work productivity reduced by ≥50% due to arthritis* | 6.8 | 2.9 | 3.5 | −3.9 (−5.8 to −2.2) (<0.001) | −3.4 (−5.3 to −1.5) (<0.001) |
| Days missed of family, social or leisure activities due to arthritis | 2.8 | 1.1 | 1.0 | −1.7 (−3.1 to −0.5) (0.005) | −1.8 (−3.2 to −0.6) (0.004) |
| Days with outside help hired due to arthritis | 1.9 | 0.7 | 1.5 | −1.2 (−2.4 to −0.3) (0.008) | −0.4 (−1.7 to 1.0) (0.582) |
| Rate of arthritis interference with household work productivity† | 4.1 | 2.2 | 2.6 | −1.8 (−2.5 to −1.2) (<0.001) | −1.5 (−2.1 to −0.8) (<0.001) |
*Does not include days counted in the previous question, ‘Work days missed due to arthritis’.
†0–10 scale, where 0=no interference, 10=complete interference.
CZP, certolizumab pegol; LOCF, last observation carried forward; Q2W, every 2 weeks; Q4W, every 4 weeks; RS, randomised set.